← Leaderboards
Margaret Louise Salisbury
Vanderbilt University Medical Center
$4,266,658
Attributed
$4,266,658
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,266,658 · 5
By mechanism
P01$1,844,608 · 2
K23$856,202 · 1
R01$797,845 · 1
R56$768,003 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Julie Anne Bastarache$14,929,100
- Richard M Peek$40,629,039
- Lorraine B Ware$25,185,641
- Cathy Shyr$430,224
- Ravi Shah$14,155,608
Others in their field
Other Emerging Leaders on “Pulmonary Fibrosis”
- Jennifer Cohen Price · University Of California, San Francisco$9,253,676
- Thomas Dick · Rbhs-New Jersey Medical School$6,611,393
- Peter J Leary · University Of Washington$5,643,326
- Justin M Oldham · University Of California At Davis$5,034,691
- Giovanni Ligresti · Mayo Clinic Rochester$4,830,216
- Oliver Eickelberg · University Of Pittsburgh At Pittsburgh$4,701,908
Research focus
Pulmonary FibrosisLungSamplingBiologicalDiagnosisClinical TrialsResearch PersonnelMeasurementCollaborationsClinical ResearchAdultProceduresResourcesTherapeutic InterventionFibrosisInterstitialDisease ProgressionImmune ResponseDesignBronchoalveolar Lavage FluidCohortPulmonary FunctionParticipantMichigan
Grant awards (11)
Reconceptualizing Disease Progression in Pulmonary Fibrosis$797,845
R01 · FY2025 · HL · contact PI
Clinical Core$404,241
P01 · FY2025 · HL · contact PI
Project 2: Environmental exposures in pre-clinical FPF$404,240
P01 · FY2025 · HL · contact PI
Clinical Core$636,177
P01 · FY2024 · HL · contact PI
Project 2: Environmental exposures in pre-clinical FPF$399,950
P01 · FY2024 · HL · contact PI
Defining the biologic and physiologic trajectory of presymptomatic through advanced pulmonary fibrosis$768,003
R56 · FY2023 · HL · contact PI
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia$146,556
K23 · FY2023 · HL · contact PI
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia$156,276
K23 · FY2022 · HL · contact PI
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia$184,458
K23 · FY2021 · HL · contact PI
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia$184,458
K23 · FY2020 · HL · contact PI
Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia$184,454
K23 · FY2019 · HL · contact PI